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Of all special fields in medicine,
internal medicine and psychiatry
probably play the most important
roles in general medical practice.
This has always been so, but there
has also always been a gap between the clinical approach to the
medical aspects of the total treatment of a person, and to the psychiatric aspects. This gap, which
for many years has alienated psychiatry from the other parts of
medicine, has only been bridged in
the last two decades. Since the
early 1950's psychiatric thinking
and practice has moved much closer
to general medical procedures, so
that treatment of many psychiatric
patients has become more rational,
more understandable and more
practical for the non-specialist.
If psychiatric treatment today is
a major concern of general medical
practice, psychopharmacology has
been one of the most important factors in this development. New
and effective pharmacological treatments of various psychiatric disorders have made it possible for
any physician to treat patients who
previously had to be hospitalized
and could be treated only by psychiatrists. In making this claim for
the pharmacotherapy of psychiatric disorders, I do not wish to imply that the fine arts of interviewing, listening and psychological
understanding are no longer needed
by the doctor; they still are and
probably always will be among the
most important skills of any good
physician. I simply want to make
the point that psychopharmacology
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today has grown into a system of
empirical and rational procedures
which can be studied and acquired
by anyone who is motivated to do
so. To acquire knowledge and skill
of psychopharmacological procedures neither calls for particular
assets of temperament or personality nor dedicated immersion into
esoteric speculations and polysyllabic terminology.
What is Psychopharmacology?
Psychopharmacology is a new
scientific discipline which was born
in the first few years of the second
half of our century. It is a discipline
which deals with psychotropic or
psychoactive drugs, i.e., drugs
which influence consciousness,
mood and behavior. Psychopharmacology, which has played such an
important role in bringing psychiatry back into the fold of general
medicine, is concerned with four
principal aspects of psychotropic
drugs: 1) indications for, and dosage of, psychotropic drugs; 2) side
effects and complications of these
drugs and their management; 3)
understanding of the mechanisms of
action of psychotropic drugs
through the development of operationally defined and measurable research procedures; 4) development
and screening of new substances in
this field. The first two of these aspects primarily concern the clinician ; the latter two lie more within
the field of the researcher.
Following the discovery of chlorpromazine, the first of a group of
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entirely new drugs for the treatment of mental disorders, it became
clear within a few years that the
new psychotropic drugs had made
a tremendous impact on three
areas: 1 ) the public, for whomvirtually overnight-tranquilizers
became a household word and a
multimillion-dollar business; 2) research, where the new discipline
of psychopharmacology was established in the wake of these discoveries; 3) treatment, where the new
drugs made possible an almost revolutionary new approach to the
therapy for many psychiatric disorders.
A number of psychotropic drugs
have, of course, been known and
used by man for a long time. Alcohol, caffeine and certain narcotics are the oldest psychotropic
agents known. The discovery of
their properties has been lost in
the dawn of recorded history. But
with the advent of scientific medicine, systematic research during the
past century led to the development of anaesthetic drugs and,
later, to the introduction of a variety of hypnotic and sedative
agents. Thus, after the empirical
discovery of intoxicants and stimulants, medical research discovered
remedies for some of the universal
ills of mankind, i.e., pain, insomnia
and anxiety. Effective drugs for
more specific uses in the treatment
of mental and emotional disorders
have been systematically developed
since two French psychiatrists, Delay and Deniker (1952), administered chlorpromazine (Thorazine)
for the first time to agitated psychotic patients and noted the
extraordinary tranquilizing effect of
this drug.
Pharmacotherapy in Psychiatric
Disorders

Although the title of my paper
is "Psychopharmacological Procedures," what I really intend to talk
about is pharmacotherapeutics with
psychiatric patients. At this point,
I would like to remind you that
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psychiatry is less fortunate than
other branches of medicine, because (with very few exceptions)
it lacks objective criteria for diagnosis as well as knowledge about
the etiology of most of the conditions for which a psychiatrist has
to treat his patients. This does not
mean that psychiatric diagnosis is
entirely subjective, but it does mean
that practically all psychiatric diagnosis is based primarily on the observation of behavioral deviations.
The causes of the major psychoses
are still unknown, although a great
deal of promising research is going
on in this area. The origin of
neurotic disturbances is better understood but is also still subject to
controversy between proponents of
psychoanalysis, learning theory and
genetic or other somatic factors. In
spite of all these theoretical uncertainties, we now have a variety
of effective pharmacological treatments in psychiatry, and even if
their mechanisms of action are not
always clearly understood, many of
these treatments have empirically
proven their worth.
Rather than involve you in the
problems of psychiatric diagnosis
and classification, I should like to
discuss the four major symptomatic
conditions which can be effectively
treated with psychotropic drugs.
These four conditions are: 1 ) psychomotor excitement; 2) tension
and anxiety; 3) depression; 4) perceptual and cognitive disorders
(e.g., hallucinations and delusions).
Let me briefly define these wellknown behavioral deviations or
mental symptoms.
Psychomotor excitement is characterized by restless, overactive,
agitated, noisy, boisterous and disinhibited behavior; a feeling of being driven-being under pressure
-with the mood being either one
of aggressive anger or excessive
elation. Usually, pronounced psychomotor excitement is associated
with insomnia and sometimes with
clouded consciousness, i.e., confusion and delirium.
Tension and anxiety are char-

acterized by aimless restlessness and
autonomic signs of sympathomimetic (adrenergic) arousal, e.g.,
tachycardia, sweating, increased
blood pressure, mydriasis. At the
same time the patient feels uncomfortable, unable to relax andwhen not only tension but also
anxiety is present-apprehensive
and threatened in some undefinable
manner. Tense and anxious patients, as a rule, also suffer from
insomnia.
Perceptual and cognitive disorders occur mostly in psychotic conditions and indicate impaired contact with reality. Examples of
symptoms occurring in this category are: hallucinatory perceptions,
in one or several sense modalities,
without any corresponding objective stimulation; delusional ideas,
i.e., false and persistent beliefs
which cannot be corrected by rational proof that they are unfounded; a generalized thinking
disorder leading to irrational and
bizarre forms of reasoning.
Depression is behaviorally characterized either by agitation or,
more typically, by psychomotor retardation, i.e., a general slowing
down of all spontaneous and responsive activity, an overall increase of inhibition and reduction
of energy output. Most important
is the core symptom, a subjective
background of an all pervasive
feeling of dejection, pessimism and
hopelessness which not infrequently
leads to attempted or completed
suicide.
Classification of Psychotropic
Drugs

Having thus classified-though
somewhat roughly-the four principal psychiatric conditions which
can be effectively treated with psychotropic drugs, let me now give
you the brief and simple classification of psychotropic drugs which
has been proposed in the report,
"Research in Psychopharmacology," published by a World Health
Organization scientific group
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( 1967) . The report distinguishes
five categories of drugs. The first
category is Neuroleptics-often referred to as major tranquilizers or
antipsychotics-which are represented by the phenothiazines, the
butyrophenones and the thioxanthenes, as well as by the reserpine derivatives. The second category is Anxiolytic Sedativesoften referred to as minor tranquilizers-which are represented
by meprobamate and its derivatives,
chlordiazepoxide (Librium) and its
derivatives, and barbiturates. The
third category is Antidepressants,
represented by monoamine oxidase
(MAO) inhibitors or imipramine
and other tricyclic compounds. The
fourth category is Psychostimulants, represented by the amphetamines, methylphenidate (Ritalin)
and pipradrol (Meratran) and by
caffeine. The fifth category is Psychodysle pt ic s (hallucinogens),
which are mainly represented by
lysergic acid diethylamide (LSD),
mescaline, psilocybin, dimethyltryptamine (DMT) and cannabis (marijuana, hashish .o r bhang).

Clinical Applications
Psychostimulants and
Psychodysleptics

Let us first look at the last two
categories of psychostimulants and
psychodysleptics, because they have
few clinical applications and we
can rapidly dispose of them. Psychostimulants are specifically indicated for the treatment of narcolepsy. Sometimes they are useful
in states of chronic lassitude, such
as may be seen following a protracted disease, e.g., a virus infection. The amphetamines may also
be helpful in programs of weight
reduction because of their anorexogenic effect. In the treatment of
depressive conditions, psychostimulants play a very minor role, because a severely depressed patient
requires more than a "lift" or
"boost." If a depressed patient's
state of arousal is increased by a

psychostimulant, he is often rendered more tense and sleepless and
may well become more depressed.
Sometimes, but rarely, an amphetamine or Ritalin may be helpful in
the treatment of certain depressive
states, but only when the depression is in its very beginning or
already fading out. During a fullblown depression, psychostimulants
are contraindicated. Because physical tolerance of and psychological
dependence on the amphetaminelike psychostimulants develop rapidly, these drugs should only rarely
be prescribed. This is the conclusion reached in the report entitled
"Control of Amphetamine Preparations" prepared by a special committee* which had been appointed
in Britain to study the place of
the amphetamines in clinical
medicine.
The psychodysleptics, i.e., LSD
and similar drugs which produce
strange alterations of consciousness
-their current popularity notwithstanding-have no clearly established therapeutic indications. Their
use is mainly experimental, although considerable literature exists
on the use of LSD in neurotic conditions, behavior disorders and alcoholism. Whether or not these
drugs are really effective in these
disorders and, if so, in what dosage
and under which conditions, will
be shown by the outcome of a
number of controlled studies, the
results of which will not be available for another three to five years.
There is also the possibility that
the recently isolated active principle of marijuana-tetrahydrocannabinol (THC)-might find some
clinical applications, perhaps in the
treatment of depressions. At the
present time, however, the application of the entire category of psychodysleptic drugs, which manifest
their action mainly through disorganization of perceptual, cognitive

* J. Chappell, W. W. Fulton, M. M.
Glatt, W. L. Rees and C. W. M.
Wilson.

and affective processes, is still in
the experimental stage.
Therapeutic Applications of
Neuroleptics and Anxiolytic
Sedatives (Tranquilizers)
States of Excitement

Effective agents in the treatment
of acute excitement and acute or
chronic states of tension and anxiety are the neuroleptics and the
anxiolytic sedatives. Both types of
drugs are often referred to as tranquilizers. However, if one chooses
to do so, he should make a clear
distinction between the major tranquilizers (neuroleptics) and the
minor tranquilizers ( anxiolytic sedatives). There are distinct clinical
and pharmacological differences between the two types of tranquilizers. The only drugs which can effectively reduce specific psyci;otic
symptoms-hallucinations, delusions and psychotic thought disorder-are the major tranquilizers.
But both the major and the minor
tranquilizers will reduce psychomotor excitement, tension and anxiety,
although the minor tranquilizers
will do it more effectively.
Many of the anxiolytic sedatives
are highly toxic and, thus, can be
used for suicidal purposes. The
neuroleptics have a much higher
margin of safety. Anxiolytic sedatives raise the convulsive threshold
and, thus, have an anticonvulsant
effect, whereas most of the neuroleptics lower the convulsive threshold and, in high doses, may
induce convulsions. Most of the
anxiolytic sedatives can produce
tolerance and psychological dependence, and many drugs in this
category will produce physical dependence when taken in high doses
over long periods of time. The
neuroleptics produce neither tolerance nor psychological dependence.
Only anxiolytic sedatives will produce disinhibition of higher nervous processes and, thus, like
alcohol, induce a phase of increased and uncontrolled behavioral
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manifestations prior to their inhibitory action. Neuroleptics inhibit
only; they do not induce states of
transient disinhibition. On the other
hand, only neuroleptic drugs can
produce extrapyramidal side effects, e.g., parkinsonism-Iike rigidity, tremor or muscular dystonia
and dyskinesia.
Since both types of drugs, the
minor or the major tranquilizers,
can be used for the management
of acute excitement or tension and
anxiety states, what factors should
determine our choice of drugs in
these conditions? The physician
who is faced with an extremely excited patient is often inclined to
choose what he thinks would be
the most rapid way of subduing the
agitated patient, i.e., by intravenous
injection of a sedative drug. It is
not advisable to inject neuroleptic
drugs intravenously in a patient
whose reactions one does not know
very well; there may be a sudden
marked drop of blood pressure or
other undesirable complications.
Therefore, the drugs chosen for
intravenous administration should
be those belonging to the category
of anxiolytic sedatives. Barbiturates,
e.g. , sodium amytal, in doses of
250 to 500 mg; chlordiazepoxide
(Librium), in doses of 50 to 100
mg; or diazepam (Valium), in
doses of 10 to 30 mg, are often
dramatically effective in terminating a state of acute excitement.
However, occasionally the patient
does not calm down until very
large doses have been administered,
thus making the patient toxic and
comatose. This difficulty occurs
most frequently in states of hysterical excitement. Because of these
occasional complications with the
intravenous administration of anxiolytic sedatives, and also because
this type of drugs in large doses
tends to make the patient confused,
I feel that it is generally better
practice to rely on the intramuscular administration of neuroleptics
for the management of acute excitement. Most agitated patients
will settle down after an intramus154

cular injection of 50 to 100 mg
of chlorpromazine (Thorazine) or
thioridazine (Mellaril). Once
calmed by these drugs, the patients also tend to become more
rational and cooperative rather
than confused or comatose, as with
the anxiolytic sedatives.
Not every agitated patient can
be controlled with one injection of
a neuroleptic. The physician should
always consider a state of acute excitement as an acute emergency and
should no more abandon a patient
before his excitement has been
brought under control, than he
would abandon a patient before
shock or hemorrhage had been
brought under control. The effects
of an intramuscularly administered
neuroleptic manifest themselves
after about 15 to 20 minutes. If at
that time the patient is still excited,
another dose of the neuroleptic,
either equal to the first dose or
somewhat reduced, should be injected. After another 15 minutes a
third injection might be given and,
sometimes, still a fourth 15 to 20
minutes later. By that time, however, even the most excited patient
should be under control with this
cumulative intermittent or staggered
sedation.
Tension and Anxiety

The treatment of anxiety and tension states by drugs is only a symptomatic approach to the underlying
problem-a symptomatic approach
which should be limited to the
shortest possible period of time.
The treatment of choice in all anxiety states is psychotherapy, unless
the tension and anxiety is due to
physical causes, for instance, hyperthyroidism or congestive failure .
It is obvious that any physical
causes of tension and anxiety
should receive specific treatment,
but in the majority of cases, tension and anxiety are due to psychological causes, e.g., environmental stress, personality disorders or
intrapsychic conflicts. For these
conditions the treatment of choice

is psychotherapy, including the recent modifications of milieu therapy and behavior therapy.
As supportive therapy for a
limited period of time, anxiolytic
sedatives, or the minor tranquilizers, are very effective in checking
symptoms of anxiety and tension .
The neuroleptics or major tranquilizers ("major," because they are
capable of suppressing psychotic
symptoms as well as anxiety symtoms) are less effective in reducing
anxiety than the minor tranquilizers. However, the minor tranquilizers tend to produce tolerance and
drug dependence and, thus, become
dangerous drugs if prescribed in
large doses for more than two or
three weeks. Tolerance and drug
dependence do not develop with the
neuroleptics, and for this reason
one may sometimes choose to prescribe a neuroleptic drug for a patient suffering from anxiety, even
though it is likely to be Jess effective than an anxiolytic sedative.
Such a choice would be indicated
if, on the basis of the patient's previous history or his personality
structure, one has reason to believe
that he might rapidly develop psychological and, also, physical dependence on an anxiolytic sedative.
When faced with this hazard it is
often wiser to choose the second
best drug, e.g., a phenothiazine
drug in small doses rather than a
minor tranquilizer for sedation.
Of all psychiatric conditions
which a physician is called upon to
treat, anxiety is undoubtedly the
most common. It is difficult to resist the urgent demands of an anxious patient for immediate relief
from his symptoms. The doctor
mus.t learn to brace himself against
these demands and persuade his patient to settle for less than complete
relief, particularly if tranquilizing
drugs have to be prescribed for
periods exceeding two or three
weeks. Patients who present anxiety
symptoms are often highly sensitive
to side effects which may be associated with the use of major tranquilizers, and they will make every
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effort to convince the doctor that
they ought to receive a drug which
does not cause them any discomfort. However, patients should
learn to accept the comparatively
mild inconveniences of side effects,
e.g., dry mouth, stuffy nose, even
some drowsiness and lack of
energy. It is probable that major
tranquilizers produce less dependence, precisely because they tend
to produce more unpleasant side
effects than the minor tranquilizers.
When the dangers of drug toxicity,
development of tolerance and dependency are threatening, the therapeutic "elegance" of prescribing
a drug with no unpleasant side effects should definitely be disregarded.
Although barbiturates are the
principal offenders in producing
drug dependence and toxic symptoms, it is a fact that almost every
minor tranquilizer has these potentials. There is no pharmacological
reason for making a distinction between hypnotic drugs and anxiolytic sedatives. Every drug which is
used primarily for sleep induction
can also be used in smaller doses
as a daytime sedative, and every
daytime sedative (or minor tranquilizer) in larger doses will produce drowsiness and sleep. The distinction between hypnotics and
sedatives is, thus, only a question
of dosage. Minor tranquilizers
other than barbiturates, e.g., methyprylon, or Noludar (Jensen, 1960;
Peters, 1966), and glutethimide, or
Doriden (Ossenfort, 1957; Ling!,
1966), are just as likely to produce
psychological and physical dependence with dangerous withdrawal
symptoms as are the barbiturates.
To a lesser degree this is also true
for meprobamate (Equanil) and
even chlordiazepoxide (Librium)
and diazepam (Valium), although
physical dependence on the latter
two drugs is rarely seen. Librium
has the best safety record of all
minor tranquilizers; no death has
been reported with this drug, although, with large doses, a number
of suicidal attempts have been made.

The only minor tranquilizer
which seems to be free of the potential hazard of inducing physical
drug dependence is tybamate. With
this drug it has been impossible to
induce physical dependence in animals or humans under experimental
conditions, and dependence on the
drug has not been reported under
clinical conditions. This may be
due to the fact that tybamate has
an unusually short half-life in the
organism; its rapid degradation may
prevent the development of dependence through the absence of any
cumulative effects (Shelton and
Hollister, 1967). Looking for a
drug to be less likely to induce psychological dependence, we have
noted that one of the new minor
tranquilizers, hydroxyzine (Atarax),
is less likely than other sedatives
to be taken in larger doses or for
a longer time than prescribedpossibly because it causes euphoria
and disinhibition less frequently
than most of the other minor tranquilizers.
In summing up the salient features regarding clinical use of anxiolytic sedatives, we arrive at the
following conclusions. Anxiolytic
sedatives, which are also called
minor tranquilizers, differ from
hypnotic drugs only in dosage.
Pharmacological and psychological
effects of all drugs in this category
are very similar, regardless of the
chemical nature of the drug. Many
of the drugs in this category are
highly toxic; therefore, no patient
should be given a prescription for
more than 15 doses of a barbiturate
or meprobamate at one time. With
very few exceptions, all anxiolytic
sedatives tend to produce tolerance
and psychological and physical dependence. There is cross-tolerance
between all drugs in this category,
e.g., between alcohol and paraldehyde, or alcohol and Librium, or
barbiturates and Librium. Once
physical dependence on a minor
tranquilizer has developed, abrupt
withdrawal is potentially dangerous
and should always be undertaken
in a hospital setting. The safest

drug from the toxicity point of view
seems to be chlordiazepoxide; from
the point of view of physical dependence, tybamate; and from the
point of view of psychological dependence, hydroxyzine. Pharmacotherapy of anxiety and tension
symptoms is always symptomatic
and should only be used as an adjunct to other more specific therapy. One should avoid prescribing
the same minor tranquilizer for
more than two weeks, unless the
patient receives only small doses. It
is advisable for a doctor to become
familiar with three or four minor
tranquilizers at the most and to alternate their use if anxiety-relieving
drugs have to be prescribed for
more than two weeks or if special
indications, e.g., danger of suicide
or addiction are present.
Acute Psychotic States
Acute psychotic episodes frequently improve within a few days
with the use of neuroleptic (antipsychotic) drugs. In previous years
these states usually lasted for
months, and even with shock therapy more time was required for
a successful resolution of symtoms
than is required today with pharmacotherapy.
The prototype of neuroleptic
drugs is Thorazine, which still
serves as a standard against which
newer drugs in the neuroleptic category are evaluated. Thorazine is a
phenothiazine derivative, as are
most of the other antipsychotic
drugs on the market today. In recent years, the butyrophenones and
thioxanthenes, derivatives of two
other chemical structures, have
joined the phenothiazines as powerful neuroleptic agents.
The neuroleptic drugs, which are
mainly used in the treatment of
psychotic conditions, may be divided into two groups: 1) those
with side effects manifesting themselves mainly in disturbances of
autonomic functions (hypertension,
miosis, tachycardia, dry mouth,
excessive perspiration and other
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symptoms of adrenergic-cholinergic
imbalance); and 2) those with side
effects expressed mainly in the extrapyramidal system (parkinsonism, akathisia, muscular dystonia
and dyskinesia). If the drug is a
phenothiazine derivative, the nature of its side effects can usually
be predicted from the side chain
which is attached to the phenothiazine nucleus. Drugs containing a
piperazine ring in the side chain are
more potent, milligram for milligram and produce extrapyramidal
symptoms more frequently than
drugs with an aliphatic side chain
which, in turn, are more likely to
produce changes in autonomic functions and sedation and must be
given in larger doses. Despite their
designation as major tranquilizers,
not all neuroleptic drugs produce
sedation. Some of them have distinctly stimulant effects and may
even increase tension in the patient if one of their side effects
is akathisia, i.e., the inability of
the patient to remain still. The
hyperkinetic extrapyramidal symptom of akathisia, as well as the
hypokinetic symptom of rigidity,
may be so disturbing to the patient
that antiparkinsonism drugs must
be employed to counteract these
symptoms. The most frequently
used drugs for this purpose are:
trihexyphenidyl hydrochloride (Artane), benzotropine methanesulfonate (Cogentin) and procyclidine
hydrochloride (Kemadrin) . All of
these antiparkinsonism drugs have
a strong anticholinergic action. We
have found that they may produce
toxic psychotic symptoms if they
are given in daily doses exceeding
six or eight mg of Artane or Cogentin, or 15 mg of Kemadrin.
Most neuroleptic drugs have remarkably low toxicity and an extraordinarily wide therapeutic margin,
but they also have an unusually
broad range of unpleasant side effects, such as somnolence, apathy
and restlessness, extrapyramidal
symptoms, dryness of the mucous
membranes, tachycardia, hypotension, disturbances of accommoda156

tion, constipation, obesity, menstrual
irregularity and photosensitization.
Skin rashes, edema, leucopenia and
cholestatic jaundice may occur as
symptoms of idiosyncratic hypersensitivity. Rarely, agranulocytosis
and venous thrombosis are seen.
With very large doses of neuroleptics-over I 000 mg of Thorazine
a day or its dose equivalent-convulsions may occur.
Mellaril, the neuroleptic with the
lowest incidence of extrapyramidal
side effects, should not be prescribed in doses exceeding a daily
maximum of 400 to 500 mg for
more than two or three weeks,
since under those conditions it
might produce irreversible retinal
changes or dangerous cardiac arrhythmias. Doses of the drug up to
400 mg/ day seem to be well tolerated for an indefinite time.
The following is a list of the most
frequently used neuroleptics:
1) Phenothiazine derivatives with
an aliphatic structure in the side
chain: chlorpromazine (Thorazine) ; triflupromazine (Vesprin);
promazine ( Sparine) .
2) Phenothiazine derivatives with
a piperazine ring in the side chain:
perphenazine (Trilafon) ; trifluoperazine (Stelazine); prochlorperazine (Compazine); thiopropazate
(Dartal) ; fluphenazine (Prolixin;
Moditen).
3) Phenothiazine derivatives with
a piperidyl ring in the side chain:
thioridazine (Mellaril).
4) Butyrophenone derivative: haloperidol (Haldol).
5) Thioxanthene derivatives:
chlorprothixene (Taractan); thiothixene (Navane).
This list is not complete, but refers only to the more frequently
used drugs in the United States.
Specific doses for each drug can
best be obtained from the information provided by the manufacturer,
although dosage information given
on the package inserts by the manufacturer invariably tends to be on
the conservative side and frequently has to be exceeded in individual cases. Fortunately, this can

be done in most cases without particular risk because of the wide
safety margin of all neuroleptic
drugs.
Which of the many neuroleptics
should one choose? Years of careful clinical investigation have made
it very clear that for all practicali.e., clinical-purposes, no specific
indications or specific therapeutic
properties exist for any of the
neuroleptic drugs. Therefore, it is
probably best for a physician to become thoroughly familiar with two
or three neuroleptic drugs and then
restrict himself to their use. What
is essential is that adequate doses
are given over an adequate period
of time. Such specific differences
between the actions of various
neuroleptic drugs as were found to
exist were only of statistical significance and so slight that they
probably have no importance for
the clinician (Goldberg et al. ,
1967) .
What is an adequate dose? The
table on the opposite page shows
approximate therapeutic equivalences of doses of various neuroleptic drugs in comparison to
Thorazine. If I mg of Thorazine is
taken as 1 phenothiazine unit, the
clinical approximations shown in
the Table are obtained. For example, the table indicates that 10 mg
of Trilafon are equivalent to 100
mg of Thorazine, and I mg of Haldol is equivalent to 70 mg of Thorazine.
The therapeutic daily dose for
the treatment of an acute psychotic
reaction is between 400 and 1000
phenothiazine units (mg of Thorazine or the dosage equivalent of
other neuroleptic drugs). Sometimes higher daily dose levels are
required, e.g., 1000 to 2000 phenothiazine units and, occasionally, up
to 3000 or 4000 units a day. But
400 to I 000 phenothiazine units a
day will be effective in the treatment of most acute psychotic
breakdowns. If the dose is adequate, the symptoms of restlessness
and insomnia should have subsided
after one week of pharmacother-
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apy; after two weeks of treatment
the patient's anxiety, irritability, depression, suspiciousness and social
withdrawal should be significantly
reduced. Only after 8 to 12 weeks
may one expect the disappearance
of hallucinations, delusions and
thought disorder. In some patients
resolution of all symptoms may,
under adequate pharmacotherapy,
be telescoped into a few days, particularly if the breakdown has been
very sudden in onset. On the other
hand, if the above timetable indicates that the patient's symptoms
are not subsiding within the expected periods of time, it may be
necessary to increase the dose of
the neuroleptic (Lehmann, 1965a).
An acute psychotic condition is
treated preferably with intramuscular injections, at least for the first
few days; then a change to oral administration may be instituted. The
risk of giving too much of a neuroleptic drug is small if the general
framework of the recommended
dosage is followed and one or two
test doses are given to observe the
patient's initial reaction to the drug.
Maintenance Therapy of
Schizophrenics in Remission
Chronic psychotic patients and
schizophrenic patients in remission
frequently require maintenance
therapy with neuroleptic drugs for
many months-sometimes for years.
The maintenance dose in most cases
is from one-sixth to one-fourth of
the acute treatment dose. If main-

tenance therapy is interrupted, the
risk of a relapse is between 30 %
and 50 % . This risk can be reduced
to 5% or 10%, provided the patient
remains on regular follow-up therapy. At times of increased stress,
family conflicts, job changes and
similar problems, the maintenance
dose may have to be increased for a
short time; the same applies if the
patient shows signs of increasing
tension or instability. The clinical
situation is similar to that of an
epileptic patient on anticonvulsant
treatment or of a diabetic on insulin, i.e., the treatment is neither
merely symptomatic nor curative,
but corrective or compensating in
nature.
A long-acting, injectable phenothiazine drug is now available in
the form of Fluphenazine Enanthate. The usual dose is 1 cc, containing 25 mg of the drug. For individual patients it is, of course,
sometimes necessary to increase or
decrease the dose, but the great advantage of this preparation is that
the effects of one injection in most
cases last for two weeks or longer,
thus freeing the patient from the
responsibility to take medication
himself every day. All he needs to
do is return every two or three
weeks for his injection. Since Fluphenazine has a piperazine structure in its side chain, the compound
is likely to induce extrapyramidal
symptoms, and antiparkinsonism
drugs might be required to counteract these side effects.

Dose Equivalence of Various Neuroleptic Drugs
Neuroleptic Drugs
Triflupromazine (Vesprin)
Promazine (Sparine)
Perphenazine (Trilafon)
Trifluoperazine (Stelazine)
Prochlorperazine (Compazine)
Fluphenazine (Prolixin; Moditen)
Thioridazine (Mellaril)
Haloperidol (Haldol)
Chlorprothixene (Taractan)
Thiothixene (Navane)

Phenothiazine Units
3

t
10

20
6
70
1
70
1

20

It is true that probably 50% or
60 % of former schizophrenic patients are today receiving neuroleptic drug therapy for months or
years without needing it. The trouble is that we cannot tell, by any
criterion, which of the patients are
the 40 % or 50 % who will relapse
if they do not receive maintenance
therapy. If we have seen once that
a patient who did not take any
maintenance medication had a relapse, we can assume with a high
degree of probability that this patient will again relapse unless he
receives maintenance therapy. Usually, we do not have this information, because the patient is put
on maintenance therapy after the
first psychotic breakdown. In these
cases one should continue with
maintenance therapy for at least
six months and then carefully try
to withdraw the maintenance medication. Once it is known that an
individual patient requires maintenance therapy, this treatment
should have considerable priority
over all other considerations. The
question one would have to ask of
oneself is whether it is more advantageous for the patient to stop
taking his medication and be hospitalized in a psychotic state or to
continue taking his medication and
remain a normally functioning
member of the community suffering the inconvenience of certain
unpleasant side effects.
Serious complications, i.e., agranulocytosis or jaundice, very rarely
occur after the first two months of
pharmacotherapy. Unfortunately,
regular blood counts and biochemical tests have hardly more than
legal value, unless they are repeated every two days. Skin pigmentation and lens opacities (usually without effect on visual
acuity) have been described after
more than six months' medication
with high doses of Thorazine, and
recently attention has been drawn
to extrapyramidal symptoms, usually involving muscles of the
tongue and the mouth, which occur
after long-term therapy with pipera157

PSYCHOPHARMACOLOGICAL PROCEDURES

zine derivatives of the phenothiazines. (Unlike the extrapyramidal
symptoms occurring under acute
treatment conditions, these late involuntary movements are usually
irreversible. Fortunately, they occur only in a comparatively small
percentage of patients, mostly in
the older age group, and only after
more than a year of continued drug
therapy.)
Therapeutics of Antidepressants
The physician who has diagnosed
his patient as being depressed and
is considering the choice of treatment must first determine how
threatening the patient's condition
is. Is the patient acutely suicidal?
Does he refuse to take food or
medication? Is he psychotic and uncooperative? These features may
determine whether the patient can
be treated at home or must be hospitalized; they may also indicate
whether the patient should receive
immediate electro-convulsive therapy or can be treated with an
antidepressant drug. In acutely suicidal patients electro-convulsive
treatment is often indicated, since
most antidepressant drugs take
from one to three weeks to produce
notable improvement.
A differential diagnosis between
endogenous and reactive depression
is often helpful, because endogenous depressions mainly require
physical treatment, either electroconvulsive treatment or pharmacotherapy, whereas reactive depressions, which may also respond to
physical treatments, usually require
psychotherapy in addition to other
treatments. Today, the extent to
which one can really distinguish
between purely endogenous and
purely reactive depressions is becoming more and more questionable. The concept of "endoreactive" depression, which is used
in the German psychiatric literature,
reflects the state of affairs which is
frequently encountered in depressive states, i.e., one with endogenous as well as reactive components.
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However, it is still useful to attempt an assessment of the varying
degrees to which each of these
two components is present in a
given depression (Lehmann, 1965b,
1968).
Once the decision to use antidepressant drug therapy has been
made, the choice lies between drugs
belonging to the class of monoamine oxidase inhibitors and drugs
which are often referred to as tricyclic antidepressants, because their
chemical structure is characterized
by a three-ring nucleus. Examples of
the first type are: phenelzine (Nardil); isocarboxazide (Marplan);
nialamide (Niamid); tranylcypromine (Parnate) . Examples of the
second group are: 1m1pramine
(Tofranil); amitriptyline (Elavil);
desipramine (Pertofrane, Norpramin); nortriptyline (Aventyl);
protriptyline (Vivactil, Triptil).
The monoamine oxidase inhibitors
have approximately the same therapeutic effectiveness as the tricyclic
antidepressants, although there is
gradually increasing evidence that
the tricyclic antidepressants are
slightly more effective than the
MAO inhibitors. On the average,
about 60% to 65% of depressed
patients show a satisfactory improvement within two to three
weeks when treated with antidepressant drugs.
The physician who prescribes a
MAO inhibitor must remember
that the effect of this enzyme inhibitor is reaching farther than ordinary drug action, because the inhibition of monoamine oxidase is
not easily reversed. Monoamine
oxidase is the enzyme that degrades
serotonin and noradrenaline, and
when this enzyme is inhibited, the
biogenic amines are allowed to accumulate. A similar effect is produced
by the tricyclic antidepressants,
but through a different mechanism; they prevent excessive noradrenaline, which has been freed at
the neuronal synapses, from being
reabsorbed into the cell body. Both
classes of antidepressant drugs, thus,
lead to an increase of available

serotonin and noradrenaline at
neuronal synapses. This has been
advanced as an explanation of
their antidepressant action, since
current neurochemical theories of
depression propose that the underlying physical substrate of a depressive state is a reduction of the
biogenic amines at the synapses of
the central nervous system.
Some MAO inhibitors, e.g.,
tranylcypromine (Parnate), have an
immediate amphetamine-like stimulating and euphorizing effect in
addition to their principal antidepressant action, which can be observed only after one to three
weeks. Such stimulation is often desirable, but in some cases it might
be contraindicated. The side effects
of MAO inhibitors are more difficult to manage than those of the
tricyclic antidepressants, because
MAO inhibitors are incompatible
with many other drugs and with
certain food substances, e.g., cheese,
which may contain the pressor substance tyramine. It is essential that
patients receiving a MAO inhibitor abstain from these food items
and from most other drugs, particularly adrenaline, amphetamines,
thyroid and Demerol which, in
combination with a MAO inhibitor, may precipitate very alarming
toxic complications. MAO inhibitors and tricyclic antidepressants
should not be administered simultaneously, and at least a week
should elapse after discontinuation
of a MAO inhibitor before treatment with a tricyclic antidepressant is instituted.
Tricyclic antidepressants produce
mainly anticholinergic side effects;
hence, care should be exercised
when ordering these drugs for patients in whom urinary retention
or glaucoma may be precipitated.
A tricyclic antidepressant should
never be administered concurrently
with both an antiparkinsonism drug
and a neuroleptic, since all three
drugs-particularly the first twohave anticholinergic properties and
may act synergistically to produce
dangerous and even fatal complica-
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tions, e.g., adynamic ileus (Warnes,
Lehmann and Ban, 1967). Some
caution is also indicated in patients
with myocardial damage in whom
tricyclic antidepressants may produce reversible cardiac arrhythmias.
Some antidepressant drugs, e.g.,
amitriptyline (Elavil), also have
anxiety-reducing effects. Patients
suffering from an anxious or agitated type of depression often respond favorably to minor or major
tranquilizers, e.g., Equanil, Librium
or Mellaril. Anxiety is very frequently associated with depression,
and since the manifestations of
anxiety are far more conspicuous
than the manifestations of depression, there is a danger that the lessening of anxiety in response to a
drug is mistaken for an overall improvement in the depressed patient's condition. If this happens,
one may relax one's vigilance when
treating a patient who, in initial
response to therapy, may sleep better, look better and display less
anxiety, but may still feel depressed
and hopeless and may also still be
suicidal. The core symptom of depression is a feeling of sadness,
despair, pessimism and hopelessness and the inability to get involved with things or people. Until
these core symptoms have subsided,
a depressed patient's improvement
is far from complete.
After the depressed patient's
symptoms have disappeared, drug
therapy should be continued for at
least two to three months at the
same dosage; after this time the
dose of the antidepressant might
be reduced to about one-half or
one-third for another month or
two.
For patients with frequently recurrent depressions or patients who
have many recurring manic or depressive episodes, lithium has recently been shown to offer valuable
prophylactic action. The therapeutic effects of lithium carbonate in
states of manic excitement have
been known for 20 years. However,
the drug seems to have few, if
any, therapeutic effects in depres-

sive states. Recently, Baastrup and
Schou ( 1967) have shown that
lithium carbonate, in doses of about
one-third or one-half of the therapeutic dose in manic conditions,
can be given as successful maintenance treatment to prevent the .
recurrence of both manic or depressive episodes. This is a considerable step forward , because
maintenance treatment for affective
disorders previous to the introduction of lithium treatment has by no
means been as effective as maintenance treatment of schizophrenic
patients in remission. However, before treatment with lithium carbonate is instituted , a careful history
should be taken and the differential diagnosis should be well
established, since this form of therapy does not seem to be effective
in schizophrenic conditions and
would not be indicated for manic
or depressive episodes which occur
only at long intervals. Since lithium
may cause dangerous toxic complications which may be fatal, it is
essential for patients on lithium
therapy to have their lithium blood
level monitored at regular intervals.
Alcoholism and Antabuse
Drugs are of no value in the
treatment of most personality disorders, for instance, antisocial behavior and sexual deviation. Some
drugs can play an important role
in the rehabilitation of opiate addicts, e.g. , methadone, which, in the
first few years of a large-scale trial
in New York City, has shown remarkable results (Dole, Nyswander
and Warner, 1968 ; Methadone
Maintenance Evaluation Committee, 1968). However, the treatment
of addicts has not yet progressed to
the point where the non-specialist
may be advised to undertake it.
But there is one kind of addiction,
i.e., alcoholism, which is so widespread-there are over two million
alcoholics in the United Statesthat non-specialist physicians must
accept a major part of the responsibility for treating this group of

patients. Treatment of the alcoholic is a complex problem and
involves the application of almost
every medical skill, but in the
framework of this discussion, I want
to draw your attention to one pharmacotherapeutic approach which is
specifically applicable to the treatment of alcoholism. I am referring
to the use of disulfiram (Antabuse)
as a maintenance treatment for alcoholics who are motivated to give
up drinking.
Antabuse is an enzyme inhibitor
which blocks the breakdown of alcohol in the organism at the acetaldehyde stage. Since acetaldehyde is
a highly toxic substance, people
who have taken Antabuse and later
take alcohol become very ill within
a matter of minutes. The alcoholic
who takes his Antabuse medication
regularly will usually be deterred
from taking alcohol by his knowledge of the ordeal he would have
to endure. The drug thus serves as
a chemical straitjacket, a most valuable aid to those who are seriously motivated to give up drinking, but is not of much value to
those who simply stop taking Antabuse when they feel the desire to
drink.
Summary
Psychopharmacology has opened
the door to many previously blocked
parts of psychiatric therapy. It has
been a welcome catalyst for a long
awaited rapprochement between
psychiatry and the rest of medicine.
Even if psychopharmacological research is not likely to produce another revolutionary "breakthrough"
type of drug in the near future,
there is good reason to expect many
more useful therapeutic tools to issue from such research in the years
to come.
References
P. C. AND M. SCHOU.
Lithium as a prophylactic agent. Its
effect against recurrent depressions
and manic-depressive psychosis.

BAASTRUP,

159

PSYCHOPHARMACOLOGICAL PROCEDURES

Arch. Gen. Psychiat. 16 : 162-172,
1967.
Control of amphetamine preparations.
Brit. Med. J. 4 : 572-573, 1968.
DELAY, J. AND P. DENIKER. Le traitement des psychoses par une methode neurolytique derivee de l'hibernotherapie. (Le 4560 RP utilise seul
en cure prolongee et continue.)
Congres des Psychiatrie des Langues
Franc;aise, Luxembourg, 22-26 July,
1952.
DOLE, V. P., M. E. NYSWANDER AND
A . WARNER. Successful treatment
of 750 criminal addicts. JAMA
206:2708-2711 , 1968.
GOLDBERG, s. C., N . MATI'SSON, J. 0.
COLE AND G. L. KLERMAN. Prediction of improvement in schizophrenia under four phenothiazines. Arch.
Gen. Psychiat. 16:107-117, 1967.
JENSEN, G. R. Addiction to noludar.
A report of two cases. New Zealand
Med. J. 59:431-432, 1960.
LEHMANN, H. E. Drug treatment of
schizophrenia. In Psychopharmacology. N. S. Kline and H. E. Lehmann
(eds.). Boston: Little, Brown,
l965a, pp. 717-751.
- - - . Problems of differential diagnosis and choice of therapy in
depressive states. Psychosomatics
6:266-272, 1965b.
- - - . Clinical perspectives on antidepressant therapy. Am. J. Psychiat.
124 (Suppl.): 12-21, 1968.
LINGL, F. A . Irreversible effects of
glutethimide addiction. Am. J.
Psychiat. 123: 349-351, 1966.
Methadone Maintenance Evaluation
Committee. Progress report of evaluation of methadone maintenance
treatment program as of March 31,
1968. JAMA 206 :2712-2714, 1968.
OSSENFORT, w. F . Drug addictions.
Dallas M ed. J. 43:229-232, 1957.
PETERS, U. H . Kombination von Noludar und Alkohol. Sucht und einmalige Vergiftungen. Med. Klin.
(Munich) 61: 1455-1458, 1966.
Research in psychopharmacology. Report of a WHO scientific group.
World Health Organ. Tech. Rep.
Ser. 371:1-39, 1967.
SHELTON, J. AND L. E. HOLLISTER.
Simulated abuse of tybamate in
man. Failure to demonstrate withdrawal reactions. JAMA 199 :338340, 1967.
160

Tranquilizer Proves Non-Addictive in
Study, editorial. Medical World
News 6:66, 1965.
WARNES, H ., H. E. LEHMANN AND T .
A. BAN. Adynamic ileus during psychoactive medication : A report of
three fatal and five severe cases.
Can. Med. Assoc. J. 96: 1112-1113,
1967.

